Valuation
- Market cap
- 58,135,000
- Revenue TTM
- $30,000
- Net income TTM
- $-14,290,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -47,633.33%
- Debt to equity
- 0.00
Trading
- Volume
- 345,000
- Avg volume
- 205,148
- Day's range
- $1.09 – $1.14
- Shares out
- 51,906,000
- Stochastic %K
- 33%
- Beta
- 0.67
- Analysts
- Strong Sell
- Price target
- $3.17
Company profile
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for...
Show more
Talphera, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. The company's lead product candidate, Niyad, is a lyophilized formulation of nafamostat that acts as a regional anticoagulant for infusion into the extracorporeal circuit. It is also developing LTX-608, a lyophilized vial containing nafamostat for IV infusion for disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and an anti-viral treatment; Fedsyra, an ephedrine pre-filled syringe for injection; and a phenylephrine pre-filled syringe for injection. The company was formerly known as AcelRx Pharmaceuticals, Inc. and changed its name to Talphera, Inc. in January 2024. The company was incorporated in 2005 and is headquartered in San Mateo, California.
- Industry
- Drug Manufacturers - Specialty & Generic
- Sector
- Healthcare
- Phone
- 650 216 3500
- Website
- https://talphera.com
- Address
- 1850 Gateway Drive, Suite 175, San Mateo, United States
Latest news
No headlines yet.
